Who Pays My Doctor?

Healthcare provider profile · identity verified

Ashte Collins, M.D.

Allopathic & Osteopathic Physicians|Internal Medicine|Nephrology · WASHINGTON, DC · NPI 1295902625

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Ashte Collins, M.D. received $243,984.74 in general payments during 2025 across 550 reported records.

Travere Therapeutics, Inc. accounted for 40.9% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 13 associated products.

A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Lokelma, Velphoro, Veltassa.

AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 123 claims for Farxiga by this doctor in 2024.

AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Lokelma by this doctor in 2024.

Fresenius USA Marketing, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VELPHORO as an associated drug or biological on 8763 records involving 2642 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Velphoro by this doctor in 2024.

Vifor Pharma, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Veltassa as an associated drug or biological on 5970 records involving 2480 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Veltassa by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$243,984.74

550 reported records · 12 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported companyCanonical companyAmountShareRecordsYear
Travere Therapeutics, Inc. Unresolved — no canonical attribution shown $99,743.2140.9%1802025
AKEBIA THERAPEUTICS INC Unresolved — no canonical attribution shown $98,891.2240.5%2952025
Otsuka America Pharmaceutical, Inc. Unresolved — no canonical attribution shown $21,498.108.8%252025
Mallinckrodt Hospital Products Inc. Unresolved — no canonical attribution shown $15,738.006.5%162025
AstraZeneca Pharmaceuticals LP Unresolved — no canonical attribution shown $5,406.682.2%132025
Novo Nordisk Inc Unresolved — no canonical attribution shown $2,207.200.9%22025
Ardelyx, Inc. Unresolved — no canonical attribution shown $188.280.1%62025
GlaxoSmithKline, LLC. Unresolved — no canonical attribution shown $124.800.1%52025
Fresenius USA Marketing, Inc. Unresolved — no canonical attribution shown $80.440.0%32025
Amgen Inc. Unresolved — no canonical attribution shown $65.110.0%32025
Novartis Pharmaceuticals Corporation Unresolved — no canonical attribution shown $21.620.0%12025
Vifor Pharma, Inc. Unresolved — no canonical attribution shown $20.080.0%12025

What were the payments for?

Payment categories

CategoryAmountRecords
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program$104,815.0065
Compensation for serving as faculty or as a speaker for a medical education program$56,850.0025
Travel and Lodging$47,334.81253
Consulting Fee$25,200.0011
Food and Beverage$9,784.93196

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported productTypeReported companyRelated amount*RecordsYear
Vafseo
Normalized: vafseo		 Drug AKEBIA THERAPEUTICS INC $98,891.22 295 2025
Source payment records
Filspari
Normalized: filspari		 Drug Travere Therapeutics, Inc. $79,555.14 151 2025
Source payment records
JYNARQUE
Normalized: jynarque		 Drug Otsuka America Pharmaceutical, Inc. $21,397.99 21 2025
Source payment records
ACTHAR
Normalized: acthar		 Biological Mallinckrodt Hospital Products Inc. $15,738.00 16 2025
Source payment records
LOKELMA
Normalized: lokelma		 Drug AstraZeneca Pharmaceuticals LP $5,286.12 7 2025
Source payment records
IBSRELA
Normalized: ibsrela		 Drug Ardelyx, Inc. $188.28 6 2025
Source payment records
BENLYSTA
Normalized: benlysta		 Biological GlaxoSmithKline, LLC. $124.80 5 2025
Source payment records
FARXIGA
Normalized: farxiga		 Drug AstraZeneca Pharmaceuticals LP $102.60 5 2025
Source payment records
VELPHORO
Normalized: velphoro		 Drug Fresenius USA Marketing, Inc. $80.44 3 2025
Source payment records
TAVNEOS
Normalized: tavneos		 Drug Amgen Inc. $65.11 3 2025
Source payment records
Wegovy
Normalized: wegovy		 Drug Novo Nordisk Inc $27.20 1 2025
Source payment records
Fabhalta
Normalized: fabhalta		 Drug Novartis Pharmaceuticals Corporation $21.62 1 2025
Source payment records
Veltassa
Normalized: veltassa		 Drug Vifor Pharma, Inc. $20.08 1 2025
Source payment records

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

Open Payments productPayment yearPart D brandPart D yearClaimsMatch methodSource
FARXIGA
farxiga		 2025 Farxiga 2024 123 exact normalized Medicare Part D
LOKELMA
lokelma		 2025 Lokelma 2024 45 exact normalized Medicare Part D
VELPHORO
velphoro		 2025 Velphoro 2024 23 exact normalized Medicare Part D
Veltassa
veltassa		 2025 Veltassa 2024 16
Beneficiary count suppressed		 exact normalized Medicare Part D

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying companyPayment yearDrug reported by same entityOpen Payments evidencePart DClaimsBeneficiaries
AstraZeneca Pharmaceuticals LP
Exact reporting entity; no affiliate inference		 2025 FARXIGA
open payments reported associated product		 CMS Open Payments — General Payments
106133 supporting records · 42906 recipient NPIs · example record 1206131362 		Farxiga · 2024
Exact normalized brand match · 1 Part D row		 123 29
AstraZeneca Pharmaceuticals LP
Exact reporting entity; no affiliate inference		 2025 LOKELMA
open payments reported associated product		 CMS Open Payments — General Payments
6897 supporting records · 4326 recipient NPIs · example record 1206131624 		Lokelma · 2024
Exact normalized brand match · 1 Part D row		 45 14
Fresenius USA Marketing, Inc.
Exact reporting entity; no affiliate inference		 2025 VELPHORO
open payments reported associated product		 CMS Open Payments — General Payments
8763 supporting records · 2642 recipient NPIs · example record 1244803773 		Velphoro · 2024
Exact normalized brand match · 1 Part D row		 23 11
Vifor Pharma, Inc.
Exact reporting entity; no affiliate inference		 2025 Veltassa
open payments reported associated product		 CMS Open Payments — General Payments
5970 supporting records · 2480 recipient NPIs · example record 1172020739 		Veltassa · 2024
Exact normalized brand match · 1 Part D row		 16 suppressed by CMS

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

BrandGenericClaimsBeneficiaries
CarvedilolCarvedilol13441
FarxigaDapagliflozin Propanediol12329
Nifedipine ErNifedipine10236
Amlodipine BesylateAmlodipine Besylate10035
Sevelamer CarbonateSevelamer Carbonate9537
FurosemideFurosemide9037
Atorvastatin CalciumAtorvastatin Calcium7828
GabapentinGabapentin7017
Hydralazine HclHydralazine Hcl5714
AllopurinolAllopurinol5520
Losartan PotassiumLosartan Potassium5121
TelmisartanTelmisartan48suppressed
SpironolactoneSpironolactone4716
JardianceEmpagliflozin46suppressed
LokelmaSodium Zirconium Cyclosilicate4514
Pantoprazole SodiumPantoprazole Sodium4516
LisinoprilLisinopril4413
Candesartan CilexetilCandesartan Cilexetil4315
CalcitriolCalcitriol3817
ChlorthalidoneChlorthalidone3413
ClonidineClonidine32suppressed
EliquisApixaban3112
HydrochlorothiazideHydrochlorothiazide28suppressed
ValsartanValsartan2611
Doxazosin MesylateDoxazosin Mesylate24suppressed
JanuviaSitagliptin Phosphate23suppressed
VelphoroSucroferric Oxyhydroxide2311
Calcium AcetateCalcium Acetate22suppressed
Rosuvastatin CalciumRosuvastatin Calcium22suppressed
IrbesartanIrbesartan20suppressed
Lidocaine-PrilocaineLidocaine/Prilocaine20suppressed
PrednisonePrednisone20suppressed
Metoprolol SuccinateMetoprolol Succinate19suppressed
Midodrine HclMidodrine Hcl19suppressed
Tramadol HclTramadol Hcl18suppressed
Clonidine HclClonidine Hcl17suppressed
Trazodone HclTrazodone Hcl17suppressed
Pravastatin SodiumPravastatin Sodium16suppressed
VeltassaPatiromer Calcium Sorbitex16suppressed
Chlorhexidine GluconateChlorhexidine Gluconate15suppressed
LactuloseLactulose14suppressed
Fluticasone PropionateFluticasone Propionate13suppressed
Labetalol HclLabetalol Hcl13suppressed
TorsemideTorsemide13suppressed
FamotidineFamotidine12suppressed
KerendiaFinerenone12suppressed
Levothyroxine SodiumLevothyroxine Sodium12suppressed
Amlodipine Besylate-BenazeprilAmlodipine Besylate/Benazepril11suppressed
Bisoprolol FumarateBisoprolol Fumarate11suppressed
Lantus SolostarInsulin Glargine,hum.Rec.Anlog11suppressed
MirtazapineMirtazapine11suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

YearGeneral PaymentsMain payerExplicit productsCompany overlapsPart D coverage
2025 $243,984.74 · 550 records Travere Therapeutics, Inc. ACTHAR, BENLYSTA, FARXIGA, Fabhalta, Filspari, IBSRELA, JYNARQUE, LOKELMA, TAVNEOS, VELPHORO, Vafseo, Veltassa, Wegovy 4 —
2024 — — — — Complete

Questions to ask

Questions you could discuss with your doctor

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Loaded source releases

DatasetYearPublicationSource
CMS Open Payments — General Payments 2025 2026-06-30 Original source
Medicare Part D Prescribers by Provider and Drug 2024 2026-05-06 Original source
NPPES Data Dissemination V2 current / reference data 2026-08-10 Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error